Wegovy costs around NZD $460 a month in New Zealand, and it’s entirely self-funded. Pharmac has added it to its “Options for Investment” list — meaning it’s a candidate for future public funding — but there’s no confirmed funding date. Mounjaro is also Medsafe-approved and also unfunded. SunnyPharma is an independent health-education site that doesn’t sell medication or refer you to any specific clinic; here’s what the current cost actually is, what changes if funding comes through, and where the process genuinely stands.
Current cost (unfunded)
~NZD $460/month
Pharmac funding status
Options for Investment — not funded
If funded, likely cost
Standard $5 prescription fee
Mounjaro funding status
Also unfunded
How much does Wegovy actually cost right now?
Wegovy has been available in New Zealand pharmacies since July 2025, approved by Medsafe as safe and effective for weight management. It is not funded by Pharmac, so the full cost falls on the patient — reported at around $460 a month, though the exact price varies by pharmacy and can run from roughly $400 to $500+ depending on dose and supplier. There is no Pharmac subsidy reducing this price; the $460 figure is what most people are actually paying today.
Where things stand with Pharmac funding
In May 2026, Pharmac added semaglutide (Wegovy) to its “Options for Investment” list — the register of medicines Pharmac would fund if its budget allowed. Being on this list is a real step, but it is not a funding decision and comes with no confirmed timeline. Pharmac’s own guidance is direct about this: if a doctor prescribes Wegovy or Mounjaro today, you will need to pay for it yourself — Pharmac does not control or subsidise that price while the medicine remains unfunded.
If Wegovy is eventually funded, the eligibility criteria under consideration are a BMI of 50 or more, or a BMI of 35 or more with at least two related health conditions (such as high blood pressure, obstructive sleep apnoea, or diabetes). Funding would also come with Special Authority restrictions limiting which prescribers can approve it. None of this is confirmed or scheduled — it reflects the criteria proposed alongside the Options for Investment listing.
Wegovy vs. Mounjaro: cost and funding compared
Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are Medsafe-approved for weight management in New Zealand, and both are currently unfunded by Pharmac — this isn’t a case of one drug being covered and the other not, as it is in some other countries. Comparing starting costs, Wegovy tends to run somewhat lower than Mounjaro, though both increase as the prescribed dose is titrated upward over the first months of treatment.
| Medication | Pharmac funding | Approx. monthly cost |
|---|---|---|
| Wegovy (semaglutide) | Not funded (on Options for Investment list) | ~$460, range ~$400–$500+ |
| Mounjaro (tirzepatide) | Not funded | Varies by dose, generally higher than Wegovy’s starting cost |
Where to actually get it
Both medications require a prescription from a doctor — you can’t buy them over the counter. Some people get a prescription through their regular GP; others use online telehealth services that offer consultations and prescriptions if you meet the clinical criteria. Larger pharmacy chains including Chemist Warehouse stock and dispense Wegovy in New Zealand. Prices can differ meaningfully between pharmacies, so it’s worth checking with more than one before committing to ongoing treatment. SunnyPharma doesn’t recommend or refer to specific clinics or pharmacies.
How New Zealand compares to Australia
Australia moved ahead of New Zealand on this: its Pharmaceutical Benefits Scheme (PBS) listed Wegovy for patients with established cardiovascular disease and a BMI of 35 or higher, cutting the cost to roughly AU$25 per script (about NZD $29), or AU$7.70 (about NZD $9) for concession card holders. New Zealand has not reached this stage — Wegovy remains on Pharmac’s investment list rather than an active subsidy, so the price gap between the two countries is currently substantial.
Frequently Asked Questions
Is Wegovy funded by Pharmac in New Zealand?
No. Wegovy is Medsafe-approved but not funded by Pharmac. It was added to Pharmac’s “Options for Investment” list in May 2026, which means it’s a candidate for future funding, but there’s no confirmed date or guarantee.
How much does Wegovy cost per month in NZ?
Around $460 a month, though the exact price varies by pharmacy and dose, generally ranging from about $400 to $500 or more.
Is Mounjaro funded in New Zealand?
No. Mounjaro is also Medsafe-approved for weight management but is not currently funded by Pharmac, the same as Wegovy.
What BMI would qualify for funded Wegovy if it becomes available?
The criteria under consideration are a BMI of 50 or more, or a BMI of 35 or more with at least two related health conditions such as high blood pressure or diabetes. This is proposed, not confirmed.
How much would Wegovy cost if it gets funded?
If funded, it would likely fall under New Zealand’s standard $5 prescription fee for funded medicines — a significant drop from the current unfunded cost of around $460 a month. This is not yet confirmed.
Where can I get Wegovy in New Zealand?
You need a prescription from a doctor, either through your regular GP or an online telehealth service. Pharmacy chains including Chemist Warehouse stock it. Prices vary between pharmacies.
Why is Wegovy funded in Australia but not New Zealand?
Australia’s Pharmaceutical Benefits Scheme has already listed Wegovy for patients with cardiovascular disease and a BMI of 35 or higher, at a much lower cost. New Zealand’s Pharmac has only added Wegovy to its investment list, a step short of an active funding decision.
Sources
- Pharmac — Wegovy and Mounjaro for weight loss not funded (official notice) — pharmac.govt.nz
- RNZ — Pharmac adds Wegovy for weight loss to list for future funding — rnz.co.nz
- RNZ — Funding of weight-loss drug Wegovy expected to come swiftly — rnz.co.nz
- NZ Herald — Pharmac makes move towards funding weight loss drug Wegovy — nzherald.co.nz
This article is based on official Pharmac communications and reporting from RNZ and the New Zealand Herald. SunnyPharma does not sell or broker medication and does not recommend specific clinics or pharmacies.